Cellebrite DI (NASDAQ:CLBT) Stock Crosses Below Fifty Day Moving Average – Should You Sell?

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) passed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $11.61 and traded as low as $10.88. Cellebrite DI shares last traded at $10.89, with a volume of 6,493,762 shares trading hands.

Recent Cellebrite DI Headlines

These are some of the CLBT headlines that stood out recently:

  • Positive Sentiment: Third-quarter revenue was $149.02 million, above the $145.83 million analyst estimate. Cellebrite reported $0.17 in EPS; estimates vary, with one source calling that in line and another comparing it with a lower $0.09 consensus. Cellebrite third-quarter results
  • Positive Sentiment: Operating indicators were solid: annual recurring revenue grew 20%, trailing-12-month free-cash-flow margin was 31%, and adjusted EBITDA was $53.6 million, a 36% margin. Cellebrite third-quarter results
  • Neutral Sentiment: Chief Revenue Officer Marcus Jewell sold 393 shares, about 0.09% of his holdings, and retained 426,735 shares; the small sale is unlikely to be a major signal on its own. SEC insider transaction filing

Wall Street Analysts Forecast Growth

Several brokerages have commented on CLBT. Needham & Company LLC lowered their price objective on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a report on Friday, August 14th. Lake Street Capital reduced their price objective on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Weiss Ratings cut shares of Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, August 27th. DA Davidson reissued a “buy” rating and issued a $15.00 target price on shares of Cellebrite DI in a report on Tuesday, September 15th. Finally, JPMorgan Chase & Co. dropped their price target on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 14th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Cellebrite DI has an average rating of “Moderate Buy” and a consensus target price of $14.62.

Read Our Latest Analysis on CLBT

Cellebrite DI Price Performance

The business has a fifty day moving average of $11.61 and a 200-day moving average of $13.24. The stock has a market cap of $2.72 billion, a PE ratio of 49.50, a price-to-earnings-growth ratio of 1.95 and a beta of 1.06.

Cellebrite DI (NASDAQ:CLBT – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.08. The firm had revenue of $149.02 million for the quarter, compared to the consensus estimate of $145.83 million. Cellebrite DI had a net margin of 11.43% and a return on equity of 15.58%. As a group, equities research analysts predict that Cellebrite DI Ltd. will post 0.37 EPS for the current year.

Insider Activity at Cellebrite DI

In other news, CMO David Gee sold 4,323 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $11.36, for a total value of $49,109.28. Following the transaction, the chief marketing officer owned 135,281 shares in the company, valued at $1,536,792.16. This trade represents a 3.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Hogan sold 25,299 shares of Cellebrite DI stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $11.29, for a total value of $285,625.71. Following the transaction, the insider owned 765,249 shares in the company, valued at approximately $8,639,661.21. The trade was a 3.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 56,909 shares of company stock worth $641,890 in the last quarter. Company insiders own 5.70% of the company’s stock.

Institutional Trading of Cellebrite DI

Institutional investors and hedge funds have recently bought and sold shares of the business. Elevation Wealth Partners LLC acquired a new stake in Cellebrite DI during the 2nd quarter worth approximately $44,000. PNC Financial Services Group Inc. raised its position in shares of Cellebrite DI by 59.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 7,456 shares of the company’s stock worth $103,000 after acquiring an additional 2,785 shares in the last quarter. Pacer Advisors Inc. grew its position in shares of Cellebrite DI by 91.1% in the 1st quarter. Pacer Advisors Inc. now owns 7,607 shares of the company’s stock valued at $105,000 after buying an additional 3,626 shares during the last quarter. Ground Swell Capital LLC purchased a new position in shares of Cellebrite DI during the third quarter worth about $128,000. Finally, Quantinno Capital Management LP purchased a new position in Cellebrite DI during the 1st quarter worth approximately $150,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Company Profile

(Get Free Report)

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.

Featured Stories

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.